A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas

A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas

CD30 is a 120‐kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large‐cell lymphoma (ALCL). CD30‐targeted treatment with antibody–drug conjugates (ADCs) can lead t...

Full description

Bibliographic Details
Main Authors: Rong Wang, Liang Li, Shenghua Zhang, Yi Li, Xiaofei Wang, Qingfang Miao, Yongsu Zhen
Format: Article
Language:English
Published: Wiley 2018-03-01
Series:Molecular Oncology
Subjects:
ADC
CD30‐targeting
cytotoxicity
lymphoma
therapeutic efficacy
Online Access:https://doi.org/10.1002/1878-0261.12166

Similar Items

Similar Items